Table 2.

SRA737-related treatment-emergent adverse events of Grade 3 or higher reported by 2 or more patients overall.

Preferred term	SRA737 dose ≤ 800 mg (N = 58) n (%)	SRA737 dose > 800 mg (N = 49) n (%)	Overall (N = 107) n (%)
Any SRA737-related Grade ≥3 treatment-emergent adverse event (TEAE)	14 (24.1)	19 (38.8)	33 (30.8)
Neutropenia	4 (6.9)	5 (10.2)	9 (8.4)
Lymphocyte count decreased	3 (5.2)	0	3 (2.8)
Rash	2 (3.4)	1 (2.0)	3 (2.8)
Rash maculopapular	1 (1.7)	2 (4.1)	3 (2.8)
Thrombocytopenia	2 (3.4)	1 (2.0)	3 (2.8)
Aspartate aminotransferase increased	2 (3.4)	0	2 (1.9)
Diarrhoea	1 (1.7)	1 (2.0)	2 (1.9)
Dyspnoea	2 (3.4)	0	2 (1.9)
Fatigue	0	2 (4.1)	2 (1.9)